NCT07091526

Brief Summary

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
168

participants targeted

Target at P50-P75 for all trials

Timeline
8mo left

Started Jul 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress55%
Jul 2025Dec 2026

First Submitted

Initial submission to the registry

July 21, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 29, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

July 29, 2025

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 29, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 29, 2026

Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

1.4 years

First QC Date

July 21, 2025

Last Update Submit

December 13, 2025

Conditions

Serum Uric Acid

Keywords

Serum uric acidPancreatic cancerPancreaticoduodenectomyDistal pancreatectomy

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    Overall survival was defined as the time from diagnosis to death.

    3-5 years

Secondary Outcomes (7)

  • Recurrence-free survival

    3-5 years

  • Cost of hospitalization

    3 months

  • Length of hospital stay

    3 months

  • Pancreatic fistula

    3 months

  • Biliary fistula

    3 months

  • +2 more secondary outcomes

Study Arms (2)

High serum uric acid

The increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl).

Diagnostic Test: serum uric acid test

Low serum uric acid

The increase of after serum uric acid operation compared with that before operation \< 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl).

Diagnostic Test: serum uric acid test

Interventions

serum uric acid testDIAGNOSTIC_TEST

Detect the serum uric acid in blood sample

High serum uric acidLow serum uric acid

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Radical pancreatic cancer resection patients

You may qualify if:

  • Patients with pathologically confirmed pancreatic cancer (primary)
  • Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
  • The postoperative survival time was at least 6 weeks

You may not qualify if:

  • No surgery was performed, or only palliative surgery/ biopsy was performed
  • Patients who underwent emergency hemodialysis or plasma exchange after surgery
  • History of gout or long-term urate-lowering therapy, such as allopurinol
  • Patients are missing follow-up data
  • Hydrochlorothiazide and furosemide were used
  • Chronic kidney disease
  • Oncolytic syndrome
  • Hemolytic anemia
  • Lead poisoning
  • Hyperparathyroidism
  • Hypothyroidism
  • A tyrosinase inhibitor was used
  • Patients with nonpancreatic primary tumors
  • Pregnant or postpartum women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lanzhou, Gansu, 730000, China

RECRUITING

Related Publications (2)

  • Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061.

    PMID: 33311950BACKGROUND

  • Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16.

    PMID: 23369448BACKGROUND

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Wenbo Meng, M.D. Ph. D.

    Hepatopancreatobiliary Surgery Institute of Gansu Province

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wenbo Meng, M.D. Ph. D.

CONTACT

13919177177mengwb@163.com

Zhengping An, M.D.

CONTACT

18298415512anzhp2023@lzu.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director of Surgery

Study Record Dates

First Submitted

July 21, 2025

First Posted

July 29, 2025

Study Start

July 29, 2025

Primary Completion (Estimated)

December 29, 2026

Study Completion (Estimated)

December 29, 2026

Last Updated

December 19, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)